In a significant development for the global medical cannabis industry, Aurora Cannabis Inc., a Canadian-based leader in the field, has achieved Good Manufacturing Practice (GMP) certification from Australia’s Therapeutic Goods Administration (TGA) for its production facilities, River and Ridge. This milestone not only underscores Aurora’s commitment to quality and compliance but also marks a significant step in the company’s efforts to consolidate its footprint in the Australian market.

The TGA oversees the regulation of therapeutic goods in Australia, including their supply, import, export, manufacturing, and advertising. GMP certification from the TGA is a stringent requirement that ensures products are consistently produced and controlled according to quality standards. For Aurora, obtaining the certification means that the company can now expand its product offerings in Australia, including dried flower, resin cartridges, pastilles, and oils, all manufactured under the highest standards.

Gorana Lakic, Vice President of Quality at Aurora, expressed pride in the achievement, highlighting its addition to the company’s global certifications and reiterating its commitment to delivering premium medical cannabis products. This certification, granted on March 15, 2024, is not just a testament to Aurora’s dedication to quality but also to its support for the burgeoning Australian medical cannabis market.

Australia’s medical cannabis sector is witnessing rapid growth, with estimates suggesting it could be worth $400 million AUD. This places Australia as the largest medical cannabis market outside of North America, presenting a substantial opportunity for companies like Aurora. Through its exclusive partnership with MedReleaf Australia, Aurora is well-positioned to bring innovative and differentiated products to this expanding market.

MedReleaf Australia, now under Aurora’s parent umbrella, along with Aurora, continues to prioritize the accessibility of high-quality, reliable medical cannabis products for Australian patients. They aim to offer a broad range of products to meet patient needs and support healthcare professionals with additional patient care options. This endeavor is supported by MedReleaf Australia’s clinical support team, which provides information and assistance to doctors and healthcare professionals, further facilitating access to medical cannabis products in the country.

Aurora Cannabis’s achievement in obtaining the TGA GMP certification is a significant development in the global cannabis industry. It not only illustrates the company’s commitment to maintaining the highest standards of quality and compliance but also its dedication to playing a pivotal role in the growth and development of the Australian medical cannabis market. As Aurora continues to expand its operations and product offerings in Australia, it reaffirms its position as a pioneering force in the global cannabis industry, focused on improving lives through innovation, science, and high-quality cannabis products.